Masimo Corporation (0JZ2.L)
USD 153.86
(-0.49%)
USD 153.86
(-0.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.04 Billion USD | 0.6% |
| 2022 | 2.03 Billion USD | 64.29% |
| 2021 | 1.23 Billion USD | 8.34% |
| 2020 | 1.14 Billion USD | 21.96% |
| 2019 | 937.83 Million USD | 9.27% |
| 2018 | 858.28 Million USD | 7.54% |
| 2017 | 798.1 Million USD | 14.9% |
| 2016 | 694.62 Million USD | 10.24% |
| 2015 | 630.11 Million USD | 7.41% |
| 2014 | 586.64 Million USD | 7.2% |
| 2013 | 547.24 Million USD | 10.95% |
| 2012 | 493.23 Million USD | 12.36% |
| 2011 | 438.98 Million USD | 8.28% |
| 2010 | 405.4 Million USD | 16.12% |
| 2009 | 349.11 Million USD | 13.69% |
| 2008 | 307.07 Million USD | 19.82% |
| 2007 | 256.28 Million USD | 14.24% |
| 2006 | 224.33 Million USD | 107.93% |
| 2005 | 107.89 Million USD | 55.56% |
| 2004 | 69.35 Million USD | 48.41% |
| 2003 | 46.73 Million USD | 20.35% |
| 2002 | 38.83 Million USD | 0.0% |
| 1999 | 6.7 Million USD | 294.12% |
| 1998 | 1.7 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 504.6 Million USD | 1.67% |
| 2024 Q1 | 492.8 Million USD | -10.22% |
| 2024 Q2 | 496.3 Million USD | 0.71% |
| 2023 Q4 | 548.9 Million USD | 14.62% |
| 2023 Q3 | 478.9 Million USD | 5.18% |
| 2023 Q1 | 565 Million USD | -8.43% |
| 2023 Q2 | 455.3 Million USD | -19.42% |
| 2023 FY | 2.04 Billion USD | 0.6% |
| 2022 Q4 | 617 Million USD | 12.32% |
| 2022 Q1 | 304.24 Million USD | -7.12% |
| 2022 Q2 | 565.3 Million USD | 85.81% |
| 2022 Q3 | 549.3 Million USD | -2.83% |
| 2022 FY | 2.03 Billion USD | 64.29% |
| 2021 Q2 | 305.11 Million USD | 2.03% |
| 2021 Q1 | 299.04 Million USD | 1.35% |
| 2021 FY | 1.23 Billion USD | 8.34% |
| 2021 Q3 | 307.41 Million USD | 0.75% |
| 2021 Q4 | 327.57 Million USD | 6.56% |
| 2020 FY | 1.14 Billion USD | 21.96% |
| 2020 Q4 | 295.05 Million USD | 6.09% |
| 2020 Q3 | 278.11 Million USD | -7.59% |
| 2020 Q2 | 300.95 Million USD | 11.62% |
| 2020 Q1 | 269.62 Million USD | 8.93% |
| 2019 Q3 | 229.01 Million USD | -0.28% |
| 2019 FY | 937.83 Million USD | 9.27% |
| 2019 Q1 | 231.66 Million USD | 3.82% |
| 2019 Q2 | 229.65 Million USD | -0.87% |
| 2019 Q4 | 247.51 Million USD | 8.08% |
| 2018 Q3 | 210.58 Million USD | -0.49% |
| 2018 FY | 858.28 Million USD | 7.54% |
| 2018 Q1 | 212.95 Million USD | -5.43% |
| 2018 Q2 | 211.62 Million USD | -0.63% |
| 2018 Q4 | 223.13 Million USD | 5.96% |
| 2017 Q2 | 192.93 Million USD | 3.56% |
| 2017 Q4 | 225.18 Million USD | 16.26% |
| 2017 Q1 | 186.3 Million USD | 1.69% |
| 2017 FY | 798.1 Million USD | 14.9% |
| 2017 Q3 | 193.69 Million USD | 0.39% |
| 2016 FY | 694.62 Million USD | 10.24% |
| 2016 Q3 | 167.62 Million USD | -2.9% |
| 2016 Q1 | 171.16 Million USD | 2.33% |
| 2016 Q2 | 172.63 Million USD | 0.86% |
| 2016 Q4 | 183.2 Million USD | 9.29% |
| 2015 FY | 630.11 Million USD | 7.41% |
| 2015 Q4 | 167.27 Million USD | 9.63% |
| 2015 Q3 | 152.57 Million USD | -2.02% |
| 2015 Q2 | 155.72 Million USD | 0.77% |
| 2015 Q1 | 154.53 Million USD | -4.48% |
| 2014 Q3 | 144.11 Million USD | 2.27% |
| 2014 Q1 | 139.81 Million USD | -1.84% |
| 2014 Q4 | 161.78 Million USD | 12.26% |
| 2014 FY | 586.64 Million USD | 7.2% |
| 2014 Q2 | 140.92 Million USD | 0.79% |
| 2013 Q4 | 142.43 Million USD | 8.36% |
| 2013 Q3 | 131.44 Million USD | -4.35% |
| 2013 Q2 | 137.42 Million USD | 1.09% |
| 2013 FY | 547.24 Million USD | 10.95% |
| 2013 Q1 | 135.94 Million USD | 2.86% |
| 2012 Q3 | 119.06 Million USD | -3.02% |
| 2012 FY | 493.23 Million USD | 12.36% |
| 2012 Q4 | 132.16 Million USD | 11.0% |
| 2012 Q1 | 119.22 Million USD | 6.13% |
| 2012 Q2 | 122.77 Million USD | 2.97% |
| 2011 Q1 | 113.04 Million USD | 7.07% |
| 2011 Q3 | 104.04 Million USD | -5.04% |
| 2011 Q4 | 112.34 Million USD | 7.98% |
| 2011 FY | 438.98 Million USD | 8.28% |
| 2011 Q2 | 109.56 Million USD | -3.08% |
| 2010 Q4 | 105.57 Million USD | 4.54% |
| 2010 FY | 405.4 Million USD | 16.12% |
| 2010 Q1 | 98.76 Million USD | 6.64% |
| 2010 Q3 | 100.98 Million USD | 0.91% |
| 2010 Q2 | 100.08 Million USD | 1.33% |
| 2009 Q1 | 85.49 Million USD | 2.92% |
| 2009 Q4 | 92.61 Million USD | 5.91% |
| 2009 Q3 | 87.44 Million USD | 4.63% |
| 2009 FY | 349.11 Million USD | 13.69% |
| 2009 Q2 | 83.56 Million USD | -2.25% |
| 2008 Q1 | 71.11 Million USD | 2.65% |
| 2008 Q4 | 83.06 Million USD | 6.31% |
| 2008 Q3 | 78.13 Million USD | 4.5% |
| 2008 Q2 | 74.76 Million USD | 5.14% |
| 2008 FY | 307.07 Million USD | 19.82% |
| 2007 Q3 | 64.37 Million USD | 1.09% |
| 2007 Q1 | 58.95 Million USD | 1.05% |
| 2007 Q2 | 63.68 Million USD | 8.02% |
| 2007 FY | 256.28 Million USD | 14.24% |
| 2007 Q4 | 69.27 Million USD | 7.61% |
| 2006 FY | 224.33 Million USD | 107.93% |
| 2006 Q2 | 58.34 Million USD | 18.33% |
| 2006 Q3 | 58.34 Million USD | 0.0% |
| 2006 Q4 | 58.34 Million USD | 0.0% |
| 2006 Q1 | 49.3 Million USD | 82.8% |
| 2005 Q1 | 26.97 Million USD | 0.0% |
| 2005 FY | 107.89 Million USD | 55.56% |
| 2005 Q2 | 26.97 Million USD | 0.0% |
| 2005 Q3 | 26.97 Million USD | 0.0% |
| 2005 Q4 | 26.97 Million USD | -0.0% |
| 2004 FY | 69.35 Million USD | 48.41% |
| 2003 FY | 46.73 Million USD | 20.35% |
| 2002 FY | 38.83 Million USD | 0.0% |
| 1999 Q3 | 2.1 Million USD | 0.0% |
| 1999 FY | 6.7 Million USD | 294.12% |
| 1999 Q4 | 1.8 Million USD | -14.29% |
| 1998 FY | 1.7 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Phreesia, Inc. | 356.29 Million USD | -474.826% |
| Accuray Incorporated | 446.55 Million USD | -358.649% |
| Align Technology, Inc. | 3.86 Billion USD | 46.971% |
| Elevance Health Inc. | 171.34 Billion USD | 98.805% |
| AxoGen, Inc. | 159.01 Million USD | -1188.016% |
| Boston Scientific Corporation | 14.24 Billion USD | 85.617% |
| CVS Health Corporation | 357.77 Billion USD | 99.428% |
| Cardinal Health, Inc. | 226.82 Billion USD | 99.097% |
| Centene Corporation | 141.26 Billion USD | 98.55% |
| DaVita Inc. | 12.14 Billion USD | 83.13% |
| HCA Healthcare, Inc. | 64.96 Billion USD | 96.848% |
| Hologic, Inc. | 4.03 Billion USD | 49.182% |
| Humana Inc. | 106.37 Billion USD | 98.075% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 44.056% |
| Laboratory Corporation of America Holdings | 12.16 Billion USD | 83.159% |
| McKesson Corporation | 308.95 Billion USD | 99.337% |
| Patterson Companies, Inc. | 6.56 Billion USD | 68.818% |
| Quest Diagnostics Incorporated | 9.25 Billion USD | 77.863% |
| ResMed Inc. | 4.68 Billion USD | 56.287% |
| Henry Schein, Inc. | 12.33 Billion USD | 83.401% |
| Teladoc Health, Inc. | 2.6 Billion USD | 21.3% |
| Universal Health Services, Inc. | 14.28 Billion USD | 85.66% |
| Veeva Systems Inc. | 2.36 Billion USD | 13.351% |
| Baxter International Inc. | 14.81 Billion USD | 86.174% |
| Becton, Dickinson and Company | 19.37 Billion USD | 89.428% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 71.251% |
| Danaher Corporation | 23.89 Billion USD | 91.427% |
| Stryker Corporation | 20.49 Billion USD | 90.008% |
| Medtronic plc | 32.36 Billion USD | 93.672% |